VirionHealth is a biotechnology company developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology will provide a new class of biological antiviral active across a range of infectious diseases.

In 2013 there were nearly 19 billion upper respiratory tract infections, most of which were viral. In particular, diseases such as influenza and respiratory syncytial virus (RSV) affect millions of people ever year.

Influenza is recognized as a major global threat by governments and health agencies with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. It is estimated that Influenza causes 3 – 5 million severe cases and 250,000 – 500,000 deaths annually (WHO). Influenza remains a leading cause of death with CDC estimating in 2013 that ~57,000 US deaths were from influenza and pneumonia. RSV affects people of all ages, but is the leading cause of serious respiratory infection in young children with approximately 64 million cases a year and 160,000 deaths worldwide. Current estimates indicate that RSV is responsible for 5000 – 7500 deaths annually in England and Wales.

3 Jan 2018, VirionHealth Receives up to $4.2m from DARPA

12 Oct 2017, VirionHealth Raises Series A from Abingworth


Loading Tweet...